Globus Medical Gross Margin 2010-2022 | GMED

Current and historical gross margin for Globus Medical (GMED) over the last 10 years. The current gross profit margin for Globus Medical as of September 30, 2022 is %.
Globus Medical Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2022-09-30 $1.00B $0.74B 74.37%
2022-06-30 $0.98B $0.73B 74.36%
2022-03-31 $0.96B $0.72B 74.53%
2021-12-31 $0.96B $0.72B 74.95%
2021-09-30 $0.94B $0.70B 74.71%
2021-06-30 $0.93B $0.69B 74.54%
2021-03-31 $0.83B $0.60B 72.97%
2020-12-31 $0.79B $0.57B 72.50%
2020-09-30 $0.77B $0.56B 73.18%
2020-06-30 $0.75B $0.55B 74.06%
2020-03-31 $0.79B $0.61B 76.45%
2019-12-31 $0.79B $0.61B 77.10%
2019-09-30 $0.77B $0.59B 77.01%
2019-06-30 $0.74B $0.57B 77.12%
2019-03-31 $0.72B $0.56B 77.39%
2018-12-31 $0.71B $0.55B 77.67%
2018-09-30 $0.69B $0.54B 77.75%
2018-06-30 $0.68B $0.52B 77.33%
2018-03-31 $0.65B $0.50B 76.61%
2017-12-31 $0.64B $0.49B 76.26%
2017-09-30 $0.61B $0.46B 75.65%
2017-06-30 $0.60B $0.45B 75.84%
2017-03-31 $0.58B $0.44B 76.08%
2016-12-31 $0.56B $0.43B 76.24%
2016-09-30 $0.56B $0.43B 76.58%
2016-06-30 $0.56B $0.43B 76.44%
2016-03-31 $0.55B $0.42B 76.13%
2015-12-31 $0.55B $0.41B 75.46%
2015-09-30 $0.53B $0.40B 75.56%
2015-06-30 $0.51B $0.39B 75.63%
2015-03-31 $0.49B $0.37B 75.86%
2014-12-31 $0.48B $0.36B 76.63%
2014-09-30 $0.46B $0.35B 76.79%
2014-06-30 $0.45B $0.35B 76.89%
2014-03-31 $0.44B $0.34B 76.98%
2013-12-31 $0.43B $0.33B 76.96%
2013-09-30 $0.42B $0.33B 77.86%
2013-06-30 $0.41B $0.32B 78.68%
2013-03-31 $0.40B $0.32B 79.85%
2012-12-31 $0.39B $0.31B 80.36%
2012-09-30 $0.37B $0.30B 79.68%
2012-06-30 $0.36B $0.29B 79.61%
2012-03-31 $0.35B $0.28B 79.02%
2011-12-31 $0.33B $0.26B 79.15%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $7.506B $0.958B
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across counties world wide. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and unique surgical instruments, used in an expansive range of spinal, orthopedic and neurosurgical procedures. The spine products address the vast majority of conditions affecting the spine including degenerative conditions, deformity, tumors and trauma. Enabling Technologies are designed to enhance a surgeon's capabilities and streamline the complicated surgical procedures to be safer, less invasive, accurate and more reproducible to improve patient care and reduce radiation exposure for both patient and caregiver. The technology contains imaging, navigation and robotic assisted surgery solutions. It acquired all assets of StelKast, Inc. and Finnish engineering company Synoste Oy.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $226.442B 23.68
Edwards Lifesciences (EW) United States $48.354B 33.28
Alcon (ALC) Switzerland $36.722B 31.62
STERIS (STE) Ireland $20.456B 25.46
Teleflex (TFX) United States $11.305B 18.34
Fresenius Medical Care AG KGaA (FMS) Germany $10.584B 10.62
Penumbra (PEN) United States $9.289B 2223.46
Integer Holdings (ITGR) United States $2.380B 19.11
Glaukos (GKOS) United States $2.298B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.402B 19.97
Paragon 28 (FNA) United States $1.303B 0.00
Nevro (NVRO) United States $1.291B 0.00
Artivion (AORT) United States $0.505B 0.00